Q-omics provides the consensus-scored RTCA profile across patient tissues and cancer cell-line models. RTCA expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RTCA is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RTCA protein abundance shows 26,123 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LIHC, and HNSC as cancer lineages where RTCA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTCA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTCA survival associations across molecular data types. RTCA RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTCA RNA expression–survival associations across cancer types. High RTCA expression shows unfavorable associations in LIHC, ACC, KICH, BLCA, LGG and KIRP. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RTCA RNA expression.
This table summarizes RTCA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RTCA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTCA shows higher tumor expression in HNSC, BLCA, STAD, KIRC, LIHC and LUSC. The HNSC box plot shows higher RTCA RNA expression in tumor versus normal tissue (log2 FC = +0.822, t-test p < 0.001).
This table shows molecular features associated with RTCA in patient tissues and cancer cell lines. In patient samples, RTCA shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, RTCA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
